Author

Yoram Bouhnik

IBD management: From the present to the future (Fresenius Kabi)
IBD management: From the present to the future (Fresenius Kabi)

Yoram Bouhnik  et al.

PERFUSE: A FRENCH NON-INTERVENTIONAL COHORT STUDY OF INFLIXIMAB-NAÏVE AND TRANSITIONED PATIENTS RECEIVING INFLIXIMAB BIOSIMILAR SB2; ANALYSIS OF 24-MONTH DATA
PERFUSE: A FRENCH NON-INTERVENTIONAL COHORT STUDY OF INFLIXIMAB-NAÏVE AND TRANSITIONED PATIENTS RECEIVING INFLIXIMAB BIOSIMILAR SB2; ANALYSIS OF 24-MONTH DATA

PERFUSE: A FRENCH NON-INTERVENTIONAL COHORT STUDY OF INFLIXIMAB-NAÏVE AND TRANSITIONED PATIENTS RECEIVING INFLIXIMAB BIOSIMILAR SB2; ANALYSIS OF 24-MONTH DATA
PERFUSE: A FRENCH NON-INTERVENTIONAL COHORT STUDY OF INFLIXIMAB-NAÏVE AND TRANSITIONED PATIENTS RECEIVING INFLIXIMAB BIOSIMILAR SB2; ANALYSIS OF 24-MONTH DATA

Yoram Bouhnik  et al.

PERFUSE: A FRENCH PROSPECTIVE/RETROSPECTIVE NON-INTERVENTIONAL COHORT STUDY OF INFLIXIMAB-NAïVE AND TRANSITIONED PATIENTS RECEIVING INFLIXIMAB BIOSIMILAR SB2; INTERIM ANALYSIS
PERFUSE: A FRENCH PROSPECTIVE/RETROSPECTIVE NON-INTERVENTIONAL COHORT STUDY OF INFLIXIMAB-NAïVE AND TRANSITIONED PATIENTS RECEIVING INFLIXIMAB BIOSIMILAR SB2; INTERIM ANALYSIS

Yoram Bouhnik  et al.

PERFUSE: A FRENCH NON-INTERVENTIONAL COHORT STUDY OF ADALIMUMAB-NAÏVE AND TRANSITIONED PATIENTS RECEIVING ADALIMUMAB BIOSIMILAR SB5; BASELINE RESULTS
PERFUSE: A FRENCH NON-INTERVENTIONAL COHORT STUDY OF ADALIMUMAB-NAÏVE AND TRANSITIONED PATIENTS RECEIVING ADALIMUMAB BIOSIMILAR SB5; BASELINE RESULTS

Yoram Bouhnik  et al.

PERFUSE: A FRENCH NON-INTERVENTIONAL COHORT STUDY OF ADALIMUMAB-NAÏVE AND TRANSITIONED PATIENTS RECEIVING ADALIMUMAB BIOSIMILAR SB5; BASELINE RESULTS
PERFUSE: A FRENCH NON-INTERVENTIONAL COHORT STUDY OF ADALIMUMAB-NAÏVE AND TRANSITIONED PATIENTS RECEIVING ADALIMUMAB BIOSIMILAR SB5; BASELINE RESULTS

CHANGING THE COURSE OF CROHN’S DISEASE WITH AN EARLY USE OF ADALIMUMAB: THE CURE STUDY FROM THE GETAID
CHANGING THE COURSE OF CROHN’S DISEASE WITH AN EARLY USE OF ADALIMUMAB: THE CURE STUDY FROM THE GETAID

Yoram Bouhnik  et al.

IMPACT OF FOOD INTAKE ON THE EFFICACY OF TEDUGLUTIDE TREATMENT IN ADULT PATIENTS WITH SHORT BOWEL SYNDROME
IMPACT OF FOOD INTAKE ON THE EFFICACY OF TEDUGLUTIDE TREATMENT IN ADULT PATIENTS WITH SHORT BOWEL SYNDROME

Yoram Bouhnik  et al.

CANCER INCIDENCE IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE AND A PRIOR NON-DIGESTIVE MALIGNANCY ACCORDING TO THE IMMUNOMODULATORY THERAPY: A MULTICENTER COHORT STUDY
CANCER INCIDENCE IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE AND A PRIOR NON-DIGESTIVE MALIGNANCY ACCORDING TO THE IMMUNOMODULATORY THERAPY: A MULTICENTER COHORT STUDY

Yoram Bouhnik  et al.

VEDOLIZUMAB CLINICAL DECISION SUPPORT TOOL PREDICTS EFFICACY OF VEDOLIZUMAB BUT NOT USTEKINUMAB IN REFRACTORY CROHN'S DISEASE
VEDOLIZUMAB CLINICAL DECISION SUPPORT TOOL PREDICTS EFFICACY OF VEDOLIZUMAB BUT NOT USTEKINUMAB IN REFRACTORY CROHN'S DISEASE

Yoram Bouhnik  et al.

A TERTIARY MULTICENTER COHORT OF PATIENTS WITH CHRONIC INTESTINAL PSEUDO-OBSTRUCTION AND CROHN’S DISEASE: A RARE ASSOCIATION WITH A HIGH PREVALENCE OF MONOGENIC DISORDERS
A TERTIARY MULTICENTER COHORT OF PATIENTS WITH CHRONIC INTESTINAL PSEUDO-OBSTRUCTION AND CROHN’S DISEASE: A RARE ASSOCIATION WITH A HIGH PREVALENCE OF MONOGENIC DISORDERS

Yoram Bouhnik  et al.

IMPACT OF TED, A GLP-2 AGONIST, ON INFLAMMATORY BOWEL DISEASE-ASSOCIATED SHORT BOWEL SYNDROME: A TERTIARY SINGLE-CENTER STUDY
IMPACT OF TED, A GLP-2 AGONIST, ON INFLAMMATORY BOWEL DISEASE-ASSOCIATED SHORT BOWEL SYNDROME: A TERTIARY SINGLE-CENTER STUDY

Yoram Bouhnik  et al.

MALNUTRITION WITH LOW MUSCLE MASS IS COMMON AFTER WEANING OFF HOME-PARENTERAL NUTRITION FOR CHRONIC INTESTINAL FAILURE
MALNUTRITION WITH LOW MUSCLE MASS IS COMMON AFTER WEANING OFF HOME-PARENTERAL NUTRITION FOR CHRONIC INTESTINAL FAILURE

Yoram Bouhnik  et al.

EARLY FECAL CALPROTECTIN LEVELS PREDICT POSTOPERATIVE RECURRENCE OF CROHN’S DISEASE: DATA FROM THE REPREVIO TRIAL
EARLY FECAL CALPROTECTIN LEVELS PREDICT POSTOPERATIVE RECURRENCE OF CROHN’S DISEASE: DATA FROM THE REPREVIO TRIAL

Yoram Bouhnik  et al.

EFFECTIVENESS AND SAFETY OF TOFACITINIB IN PATIENTS WITH CHRONIC ANTI-TNF REFRACTORY ULCERATIVE PROCTITIS: A MULTICENTER COHORT STUDY FROM THE GETAID
EFFECTIVENESS AND SAFETY OF TOFACITINIB IN PATIENTS WITH CHRONIC ANTI-TNF REFRACTORY ULCERATIVE PROCTITIS: A MULTICENTER COHORT STUDY FROM THE GETAID

Yoram Bouhnik  et al.

Item 1 - 15 / 15
1